Biogen’s experimental Alzheimer’s drug diranersen slows cognitive decline in Phase 2, matching approved therapies

Biogen reported that its experimental Alzheimer’s therapy diranersen slowed cognitive decline in a mid-stage Phase 2 study, achieving decline rates similar to those seen with drugs already on the market.

The trial showed that multiple doses of diranersen improved performance on several cognitive tests compared with placebo, and the drug also reduced levels of the tau protein, which is thought to drive neurotoxicity in Alzheimer’s disease.

If the findings are confirmed in a larger Phase 3 trial, Biogen could have a new option for patients and may revive discussion about the level of efficacy needed for regulatory approval.